1	Intera	ction between placental efflux transporters and use of antiseizure or
2	antide	epressant drugs during pregnancy on birth weight in the Norwegian Mother,
3	Fathe	r and Child Cohort Study
4		
5	Marta	H. Hernandez <sup>1,2*</sup> , Jacqueline M. Cohen <sup>1,3</sup> , Karoline H. Skåra <sup>1,4</sup> , Thea K.
6	Grinds	stad <sup>1</sup> , Yunsung Lee <sup>1</sup> , Per Magnus <sup>1</sup> , Pål R. Njølstad <sup>5,6</sup> , Ole A. Andreassen <sup>7,8</sup> ,
7	Elizab	eth C. Corfield 9,10, Alexandra Havdahl 9,10,11,12, Espen Molden 13,14, Kari Furu 1,3,
8	Maria	C. Magnus <sup>1¶</sup> , Alvaro Hernaez <sup>1,2¶</sup>
9		
10	1.	Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo,
11		Norway.
12	2.	Blanquerna School of Health Sciences, University Ramon Llull, Barcelona,
13		Spain.
14	3.	Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo,
15		Norway.
16	4.	Department of Community Medicine and Global Health, Institute of Health and
17		Society, University of Oslo, Oslo, Norway.
18	5.	Center for Diabetes Research, Department of Clinical Science, University of
19		Bergen, Bergen, Norway
20	6.	Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway
21	7.	Norwegian Centre for Mental Disorders Research, NORMENT, Division of Mental
22		Health and Addiction, Oslo University Hospital, Oslo, Norway
23	8.	Institute of Clinical Medicine, University of Oslo, Oslo, Norway
24	9.	Center for Genetic Epidemiology and Mental Health, Norwegian Institute of Public
25		Health, Oslo, Norway
26	10	. Nic Waals Institute, Lovisenberg Diakonale Hospital, Oslo, Norway
27	11	. PROMENTA Research Center, Department of Psychology, University of Oslo,
28	NOTE: This	preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. USIO, NOTWAY

- 29 12. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- 30 13. Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
- 31 14. Section for Pharmacology and Pharmaceutical Department of Pharmacy,
- 32 University of Oslo, Oslo, Norway
- 33
- 34 ¶: both authors contributed equally to this work.
- 35
- 36 \*Corresponding author
- 37 E-mail: martahh1@blanquerna.url.edu (MHH)

#### 38 ABSTRACT (286 words)

Background: Intrauterine exposure to antiseizure and antidepressant drugs is
associated with adverse pregnancy outcomes, including low birth weight. Gene variants
in placental efflux transporter genes may alter foetal exposure to these drugs.

42 Methods: We investigated whether genetic variants in placental efflux transporters modified the impact of maternal antiseizure and antidepressant drug use on offspring 43 44 birth weight, using data from the Norwegian Mother, Father and Child Cohort Study and 45 the Medical Birth Registry of Norway (69,828 offspring with their genotype data, 81,189 46 with maternal genotype data). We systematically searched for gene variants in placental 47 efflux transporters influencing drug exposure [MDR1-ABCB1 (7 alleles), MRP1-ABCC1 48 (2), MRP2-ABCC2 (3) and, BCRP-ABCG2 (2)] and calculated genetic scores (sum of 49 alleles potentially related to low transporter activity). We assessed the interaction 50 between prenatal drug use and genetic scores on birth weight.

51 Findings: Prenatal antiseizure medication exposure was associated with lower birth 52 weight (-95.5 grams, 95% CI -190 to -0.78). This relationship depended on the offspring's 53 MRP2-ABCC2 genetic score. Birth weight differences between exposed vs. unexposed 54 were 70.3 g (95% CI -494 to 634) in the lowest genetic score category and -306 g (95% CI -361 to -31.8) in the highest (interaction p-value = 0.019; main variant: rs3740066). 55 56 The antiseizure medication-lower birth weight association also depended on the 57 maternal MDR1-ABCB1 genetic score. Birth weight differences between exposed vs. 58 unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category and 59 -317 g (95% CI -517 to -117) in the highest (interaction p-value = 0.037; main variants: 60 rs10248420 and rs2235015). Prenatal antidepressant exposure was associated with low 61 birth weight, but no gene-drug interactions were observed.

62 Conclusions: MRP2-ABCC2 and MDR1-ABCB1 variants may influence prenatal
63 antiseizure medication's impact on neonatal birth weight.

Keywords: antiseizure medication, birth weight, MRP2-*ABCC2*, MDR1-*ABCB1*, MoBa,
MBRN.

#### 66 SUMMARY

67

#### 68 What is already known on this topic.

- Low birth weight increases the risk of neonatal death, morbidity, and lifelong
   susceptibility to various health conditions, including neurodevelopmental,
   cardiometabolic, respiratory, and psychiatric disorders.
- Previous studies have reported an association between maternal use of centrally
   acting medication during pregnancy and low birth weight in the offspring, but the
   underlying causes remain poorly understood.
- It is of great concern to identify strategies that can modulate foetal exposure to
  these medications and enable individualised, safe use since discontinuation may
  also increase the risk of harm to the mother.

78

#### 79 What this study adds.

- Our study uncovered genetic variants in both offspring (rs3740066) and mother
   (rs10248420 and rs2235015) linked to placental efflux transporters that
   modulated the association between maternal antiseizure drug use during
   pregnancy and the risk of low birth weight in the offspring, marking the first
   exploration of such interactions.
- If these findings are confirmed and information about specific drugs is
   incorporated, this could potentially be used in the development of personalized
   recommendations for pregnant women undergoing these treatments.

#### 88 INTRODUCTION

89

90 The use of medication during pregnancy must carefully balance benefits to the mother 91 and potential harm to the offspring.<sup>1</sup> Centrally acting drugs (such as antiseizure drugs 92 [mainly lamotrigine, 0.3% of pregnancies] and antidepressants [1.5% of pregnancies]) have been increasingly used during pregnancy.<sup>2,3</sup> However, intrauterine exposure to 93 94 these medications may be associated with adverse pregnancy outcomes such as impaired foetal growth and reduced birth weight in offspring.<sup>4-6</sup> Furthermore, these 95 96 conditions are linked to a multitude of morbidities, resulting in both immediate and long-97 term adverse consequences for newborns, their families, and society.<sup>7</sup> The placenta 98 plays an essential role in substance exchange between mother and foetus (e.g., 99 nutrients, metabolic by-products). Small, non-polar, lipophilic xenobiotics such as 100 antiseizure drugs and antidepressants can pass through the placenta via passive 101 diffusion.<sup>8</sup> However, several active proteins can efflux these compounds from the foetus 102 back to the mother.<sup>9</sup> Active efflux proteins from the adenosine triphosphate-binding 103 cassette superfamily (such as P-glycoprotein, breast cancer resistance protein, and 104 others multidrug resistance proteins) are involved in the transplacental passage of drugs 105 particularly affecting the passage of centrally-acting drugs and their metabolites.<sup>10,11</sup> 106 Several antiseizure drugs and antidepressants are substrates for these transporters.<sup>12,13</sup> 107 Efflux transporters may therefore have a foetoprotective effect by lowering the 108 concentrations of potentially toxic drugs on the foetal side. Genetic variants in the 109 transporters may modify their activity and could be located in the offspring or maternal 110 genotype.<sup>14,15</sup> Little is known about the role of genetic variants in placental efflux 111 transporters on the modulation of the association of antiseizure drugs and 112 antidepressants during pregnancy with offspring outcomes such as low birth weight.

113 Our aim was to explore whether there is an interaction between the use of 114 antiseizure drugs or antidepressants during pregnancy and genetic variants related to

- 115 placental efflux transporters (in P-glycoprotein, breast cancer resistance protein, and
- 116 others multidrug resistance proteins) on offspring birth weight.

#### 117 MATERIALS AND METHODS

118

#### 119 Study participants

We included participants in the Norwegian Mother, Father, and Child Cohort Study (MoBa). MoBa is a prospective, population-based pregnancy cohort conducted by the Norwegian Institute of Public Health. Pregnant women and their partners were recruited across Norway between 1999-2008 at the time of routine ultrasound screening (~17<sup>th</sup> gestational week). The cohort includes approximately 114,000 children, 95,000 mothers, and 75,000 fathers.

126 This work used a subsample of offspring from singleton pregnancies with 127 available information on genotype and birth weight (from version #12 of the guality-128 assured data files released on May 11, 2022). Genotype data was obtained from blood 129 samples provided during pregnancy and at birth (mothers) and umbilical cord blood at 130 birth (offspring).<sup>16</sup> A total of 238,001 samples have been genotyped in 24 genotyping 131 batches with varying selection criteria, genotyping platforms, and genotyping centres.<sup>17</sup> 132 Quality control, phasing, and imputation were performed using the MoBaPsychGen 133 pipeline as previously described.<sup>17</sup>

Our work is described according to the Strengthening the Reporting of
 Observational studies in Epidemiology guidelines (Supplemental Table 3).<sup>18</sup>

136

137 Use of centrally acting drugs

We used self-reported information on the use of centrally acting drugs from MoBa questionnaires in the 18<sup>th</sup> and 30<sup>th</sup> gestational weeks.<sup>19</sup> Specifically, women were asked whether they had epilepsy or depression, and if they answered yes, whether any medications were used to treat the condition(s). This project has no information on the specific drug(s) the woman used. Any reported use of medication(s) for epilepsy (yes/no) or depression (yes/no) were categorized and evaluated separately.

144

#### 145 Birth weight

146 Data on offspring birth weight in grams was obtained from the Medical Birth Registry of

147 Norway, a national health registry which contains information about all births in Norway

- 148 since 1967.<sup>20</sup>
- 149
- 150 Covariates

151 Information on maternal age at delivery (continuous), parity  $(1, 2, 3, \ge 4)$  and sex of the 152 offspring (female/male) was obtained from the birth registry. Furthermore, information on 153 maternal years of education (continuous), pre-pregnancy body mass index (continuous), 154 having ever smoked (yes/no), and self-reported depression or epilepsy was gathered in 155 the questionnaire administered at gestational week 18.

156

157 Genetic variants related to placental transporters and genetic scores.

We performed a systematic review in PubMed, Web of Science, pharmacogenetic websites (<u>https://www.pharmgkb.org</u>) and GWAS catalog (<u>https://www.ebi.ac.uk/gwas/</u>) to identify gene variants on the adenosine triphosphate-binding cassette superfamily of placental efflux transporters (MDR1-*ABCB1*, MRP1-*ABCC1*, MRP2-*ABCC2*, and BCRP-*ABCG2*). We followed the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement.<sup>21</sup> A detailed description of the search is available in Supplemental Materials.

165 After the systematic review, we only conserved genetic variants that were not in 166 linkage disequilibrium according to linkage disequilibrium block analysis in the 1000 167 Genomes CEU and GBR populations (given the MoBa participants passing the postimputation quality control cluster with these populations;  $R^2 < 0.8$ ) and with a minor allele 168 frequency > 1%.<sup>22</sup> Genetic scores were calculated as the sum of the number of risk 169 170 alleles for all genetic variants related to each transporter in a participant. The genetic 171 score was represented in the results as a genetic score if the number of score values 172 were  $\leq 5$ . Otherwise, we represented them in quartiles. We considered a risk allele to be

the allele associated with any of these five theoretical situations potentially related to an increased exposure of the drug to the foetus: decreased function of the transporter, declined expression of the transporter, non-resistance to the treatment, higher concentrations of the drug, or more adverse effects. Information related to the studies is available in Supplemental Table 2.

178

179 Ethical approval

The MoBa study is conducted according to the Declaration of Helsinki for medical research involving human subjects. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency. It is now based on regulations related to the Norwegian Health Registry Act. Participants provided written informed consent before joining the cohort. This project was approved by the Regional Committee for Medical and Health Research Ethics of South/East Norway (reference: 2017/1362).

187

#### 188 Statistical analyses

Normally distributed continuous variables were described by means and standard
 deviations, nonnormally distributed continuous variables by medians and 25<sup>th</sup>-75<sup>th</sup>
 percentiles, and categorical variables by proportions.

192 We first assessed the relationship between maternal use of centrally acting drugs 193 during pregnancy and birth weight using multivariable linear regressions adjusted for 194 offspring sex and maternal factors (age at delivery, years of education, pre-pregnancy 195 body mass index, parity and having ever smoked). Clustered standard errors were 196 computed to account for dependence among births to mothers contributing with more 197 than one pregnancy in MoBa. To determine whether there were significant interactions 198 between maternal prenatal use of centrally acting drugs and the genetic scores on the 199 offspring birth weight, we applied likelihood ratio tests between nested linear regression 200 models with and without an interaction product-term of "exposure group x genetic score".

201 The nested models were further adjusted for the first twenty ancestry-informative genetic 202 principal components and genotyping batch. We considered any interaction with a p-203 value for the overall interaction test < 0.05 and a differential association between 204 medication use and offspring birth weight in the two extreme categories according to the 205 genetic score. Whether an interaction was found, we further explored interactions with 206 the individual variants in the genetic score as sensitivity analyses using the same 207 strategy (as these were exploratory sensitivity analyses, we here considered any 208 interaction with a p-value < 0.1).

209 Statistical analyses were performed in R Software, version 4.1.0. Our analysis

code is available in GitHub:

211 https://github.com/alvarohernaez/Gene\_psychoactivedrug\_BW\_MoBa/.

#### 212 RESULTS

- 213
- 214 Study population
- 215 In our study, we included 69,828 singleton pregnancies with offspring genotype
- 216 information and offspring birth weight, and 81,189 singleton pregnancies with maternal
- 217 genotype data and offspring birth weight (Figure 1). Mean birth weight was 3,639 grams
- 218 (SD 522). A total of 174 children (0.25%) were exposed to maternal use of antiseizure
- 219 drugs during pregnancy and 766 (1.10%) to antidepressants. Women using centrally
- acting drugs were younger (only for antiseizure drugs), had lower educational attainment,
- and were more likely to have ever smoked (Table 1).
- 222
- 223
- Figure 1. Flow chart of study participants.
- 225



**Table 1.** Baseline characteristics of mothers with offspring genotype information.

	Antiseizu	ure drugs	Antidepressants		
	Exposed	Unexposed	Exposed	Unexposed	
	( <i>n</i> = 174)	( <i>n</i> = 69,654)	( <i>n</i> = 766)	( <i>n</i> = 69,062)	
Age at delivery (years), mean ± SD	29.1 ± 4.83	30.2 ± 4.52	30.2 ± 5.07	30.2 ± 4.51	
Education years, mean ± SD	15.9 ± 3.64	17.1 ± 3.30	16.2 ± 3.63	17.2 ± 3.30	
Pre-pregnancy body mass index (kg/m <sup>2</sup> ), median (25 <sup>th</sup> -75 <sup>th</sup>	23.3 (21.6-26.4)	23.3 (21.1-25.9)	23.2 (21.1-26.6)	23.1 (21.1-25.9)	
percentiles)					
Having ever smoked, n (%)	107 (61.8%)	34,310 (50.0%)	510 (67.4%)	33,907 (49.9%)	
Previous number of deliveries:					
0, <i>n</i> (%)	64 (36.8%)	23,589 (33.9%)	261 (34.1%)	23,343 (33.9%)	
1, <i>n</i> (%)	42 (24.1%)	22,342 (32.1%)	223 (29.1%)	22,113 (32.1%)	
2, <i>n</i> (%)	44 (25.3%)	13,697 (19.7%)	156 (20.4%)	13,547 (19.7%)	
3, <i>n</i> (%)	15 (8.62%)	6,118 (8.78%)	72 (9.40%)	6,045 (8.77%)	

≥4, <i>n</i> (%)	9 (5.17%)	3,908 (5.61%)	54 (7.05%)	3,851 (5.59%)
Offspring birth weight, mean $\pm$ SD	3,516 ± 603	3,639 ± 522	3,574 ± 512	3,640 ± 522
Biological sex of the offspring:				
Female, <i>n</i> (%)	84 (48.3%)	35,549 (51.0%)	366 (47.8%)	35,267 (51.1%)
Male, <i>n</i> (%)	90 (51.7%)	34,105 (49.0%)	400 (52.2%)	33,795 (48.9%)

#### 230 Search of genetic variants on placental transporters

231 The systematic search identified 26 genetic variants in the placental transporter genes 232 associated with differences in antiseizure drugs and/or antidepressant outcomes 233 (Supplemental Figure 1), of which 14 were independent and available in the MoBa 234 genotype database (Supplemental Table 1). Seven variants were found for MDR1-235 ABCB1, two for MRP1-ABCC1, three for MRP2-ABCC2, and two for BCRP-ABCG2. We 236 used these genetic variants to calculate risk scores. The ranges of values for the four 237 genetic scores calculated were: 0 to 11 (MDR1-ABCB1; we presented the stratified 238 associations according to guartiles), 0 to 4 (MRP1-ABCC1), 2 to 6 (MRP2-ABCC2), and 239 0 to 4 (BCRP-ABCG2).

240

241 Interaction between genetic variants of placental transporters and exposure to
242 antiseizure drugs during pregnancy on birth weight

243 Antiseizure medication use during pregnancy was associated with lower birth weight (-244 95.5 g, 95% confidence interval [CI] -190 to -0.78). Greater values of the MRP2-ABCC2 245 genetic score in the offspring were associated with lower birth weight in offspring of 246 mothers who used antiseizure drugs during pregnancy. The difference in birth weight 247 between exposed vs. unexposed was 70.3 g (95% CI -494 to 634) in the lowest genetic 248 score category (2 risk alleles) and -306 g (95% CI -361 to -31.8) in the highest (6 risk 249 alleles) (p-value for interaction = 0.019; Figure 2). The variant with the strongest evidence 250 of an interaction in the sensitivity analyses of the MRP2-ABCC2 genetic score was 251 rs3740066 (p-value for interaction = 0.023; Supplemental Figure 2).

Greater values of the MDRP1-*ABCB1* genetic score in the mother were also linked to lower birth weight among offspring of mothers who used antiseizure drugs during pregnancy. The difference in birth weight between exposed vs. unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category (first quartile) and -317 g (95% CI -517 to -117) in the highest (fourth quartile) (*p*-value for interaction = 0.037; Figure 3). Variants rs10248420 and rs2235015 included in the MDRP1-*ABCB1* 

- 258 genetic score had some evidence of an interaction in the sensitivity analyses (p-values
- 259 for interactions = 0.042 and 0.058, respectively; Supplemental Figure 3).

260 Figure 2. Differences in birth weight associated with pregnancy exposure to antiseizure medication due to the genetic scores for placental





Figure 3. Differences in birth weight associated with pregnancy exposure of antiseizure medication due to the genetic scores for placental transporters in the mother.



- 266 Interaction between genetic variants of placental transporters and exposure to antidepressants
- 267 during pregnancy on birth weight
- 268 Use of antidepressant drugs during pregnancy was associated with lower birth weight (-60.5
- 269 g, 95% CI -97.6 to -23.3). However, we observed no interactions between prenatal use of
- antidepressants and any genetic score of placental efflux transporters (in offspring or mothers)
- 271 on birth weight in the offspring (Supplemental Figures 4 and 5).

#### 272 **DISCUSSION**

273

In this large population-based study, involving offspring of mothers who used antiseizure medication during pregnancy, a high genetic score for MRP2-*ABCC2* in the offspring and MDR1-*ABCB1* in the mother, suggesting a greater exposure to these drugs, was associated with lower birth weight in the offspring.

278 MDR1-ABCB1 and MRP2-ABCC2 are the only transporters located in the apical 279 membrane of the trophoblast (maternal side) and their function is to return xenobiotics to maternal circulation.<sup>23</sup> Thus, it seems plausible that genetic variants linked to lower transporter 280 281 activity are associated with higher foetal exposure and greater toxicity of antiseizure drugs. In 282 addition, the main variant in the interaction between the MRP2-ABCC2 genetic score and 283 prenatal antiseizure drug use (rs3740066) has been previously linked to a poorer response to antiseizure medication<sup>24</sup> and a higher risk of other adverse events during pregnancy 284 (intrahepatic cholestasis of pregnancy).<sup>25</sup> The differences in the interactions found within 285 286 genetic variants in the offspring (MRP2-ABCC2) and maternal genome (MDR1-ABCB1) can 287 be explained by physiological changes in the placenta structure. Early in pregnancy, the separation between the maternal circulation and the foetal circulation by the trophoblasts 288 289 villous barrier is 50-100 µm (second month). It becomes progressively thinner as the pregnancy proceeds (only 4-5 µm at term).<sup>26</sup> In addition, the total placenta surface area 290 increases from about 5 m<sup>2</sup> at 28 weeks of gestation to 12 m<sup>2</sup> at term. Thus, passive diffusion 291 292 of medications increases with gestational age, which means that medication can reach the foetal circulation more easily later in pregnancy.<sup>26</sup> At the same time, the expression of MRP2-293 294 ABCC2 increases with advancing gestational age, whereas the expression of MDR1-ABCB1 295 declines.<sup>27,28</sup> As a consequence of all these phenomena, the presence of risk alleles for MRP2-296 ABCC2 may play a more significant role in determining the offspring's exposure. However, an 297 alternative hypothesis could also explain our findings. A greater foetal exposure to medication 298 due to lower activity of the efflux transporters may also be linked to lower medication levels in 299 the mother and a poorer control of the disease. Greater disease effects in mothers may be

associated with alternative mechanisms that may also explain an increased risk of low birthweight in the offspring.

302 There could be several reasons for the lack of gene-drug interactions with 303 antidepressants. First, the association between exposure to antidepressants during pregnancy 304 and birth weight is of a smaller magnitude in our data, which can make the search of gene-305 drug interactions more challenging. Second, the accuracy of our data regarding the usage of 306 antidepressants may be less precise, as women may have varying criteria for identifying such 307 treatments. This discrepancy may not be present regarding antiseizure drugs. Finally, a larger 308 proportion of women may discontinue the use of antidepressants during pregnancy compared to antiseizure medications.29 309

310 Our study has some limitations. First, due to the unavailability of information on the 311 specific drug utilized, we conducted our analysis based on aggregated drug groups. Although 312 the main medications in each group show similar pharmacodynamic behaviour and their usage 313 during pregnancy reduces the number of medications under consideration,<sup>3</sup> this may interfere 314 with our findings because there may be variations in the medication groups' interactions due 315 to differences in transporter affinity or dose-dependent effects.<sup>26,30</sup> Second, due to the lack of 316 a genome-wide association study showing which genetic variants are associated with high or 317 low activity of efflux transporters, we calculated risk scores using studies on genetic variants 318 indirectly related to high or low activity (e.g., treatment resistance, treatment efficacy, presence 319 of adverse effects). Third, the interactions found in our data are only suggestive and our 320 findings require replication in independent populations to confirm their validity. Finally, the 321 characteristics of our participants (individuals of northern European ancestry with moderate-322 high socioeconomic status) limit our capacity to generalize our conclusions to other 323 populations.

#### 324 CONCLUSIONS

325 In summary, genetic variants in MRP2-ABCC2 and MDR1-ABCB1 placental transporters may 326 modulate the association between prenatal exposure to antiseizure drugs and low birth weight 327 in the offspring. To the best of our knowledge, this is the largest gene-drug interaction study 328 on offspring birth weight to date and it was performed in a well-characterized population with 329 genome-wide genotype information. If our findings are confirmed, particularly in studies in 330 which we know exactly which drug the mothers have used during pregnancy, the assessment 331 of these genetic variants may be implemented in clinical settings to support safer use of 332 antiseizure drugs during pregnancy.

#### 333 DATA AVAILABILITY STATEMENT

Consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to datasets for replication should apply to <u>datatilgang@fhi.no</u>. Access to datasets requires approval from the Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa.

338

#### 339 ACKNOWLEDGMENTS

The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We thank all the participating families in Norway who take part in this ongoing cohort study, and those who contributed to the recruitment and the infrastructure of the cohort.

344 We thank the Norwegian Institute of Public Health for generating high-quality genomic 345 data. This research is part of the HARVEST collaboration, supported by the Research Council 346 of Norway (project reference: #229624). We also thank the NORMENT Centre for providing 347 genotype data, funded by the Research Council of Norway (project reference: #223273), South 348 East Norway Health Authority, and Stiftelsen Kristian Gerhard Jebsen. We further thank the 349 Center for Diabetes Research (University of Bergen) for providing genotype data funded by 350 the European Research Council Advanced Grant project SELECTionPREDISPOSED, 351 Stiftelsen Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of 352 Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway 353 Health Authority.

This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated, and developed by the TSD service group at the University of Oslo, IT-Department (tsd-drift@usit.uio.no).

357 This paper does not necessarily reflect the position or policy of the Norwegian Research358 Council.

- 359
- 360

#### 361 FUNDING

The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services 362 363 and the Norwegian Ministry of Education and Research. This project received funding from the 364 European Research Council under the European Union's Horizon 2020 research and 365 innovation program (grant agreement No 947684). This work was also partly supported by the 366 Research Council of Norway through its Centres of Excellence funding scheme, project 367 number 262700 and 223273, and the project "Women's fertility - an essential component of 368 health and well-being", number 320656, and co-funded by the European Research Council 369 (grant agreement No 101071773). M.H.H. was supported by the fellowship "Estancias de 370 movilidad Jose Castillejo dentro del Programa Estatal de Promoción del Talento y su 371 empleabilidad, en el marco del Plan Estatal de Investigación Científica y Técnica y de 372 Innovación 2017-2020", from the Spanish government. P.R.N. was supported by the European 373 Research Council (grant agreement No 293574), the Novo Nordic Foundation 374 (#NNF19OC0054741) and the Trond Mohn Foundation (PRECISE-DIA). E.C. and A.Havdahl were supported by the Research Council of Norway (274611) and the South-Eastern Norway 375 Regional Health Authority (project numbers 2020022, 2021045). O.A.A. was supported by the 376 377 European Research Council (grant agreement No 964874) and the Research Council of 378 Norway (300309, 273291). The funders had no role in the study design; the collection, analysis, 379 and interpretation of data; in the writing of the report; or in the decision to submit the article for 380 publication. Views and opinions expressed in this paper are those of the authors only and do 381 not necessarily reflect those of the funders. Neither the European Union nor the granting 382 authority can be held responsible for them.

383

#### 384 CONFLICTS OF INTEREST

O.A.A. is a consultant for cortechs.ai and has received speaker's honorarium from Janssen,
Lundbeck, and Sunovion unrelated to the current work. The rest of the authors declare that no
competing interests exist.

#### 389 AUTHORS' CONTRIBUTION

390 M.H.H. conceived and designed the study, was responsible for data curation, formal analyses, 391 data interpretation, and drafting the article. J.M.C. critically revised the article and contributed 392 to interpretation of the data. K.H.S. provided support in data analysis, software use, and 393 visualization of results, and critically revised the article. T.K.W.G. was involved in the 394 interpretation of data and critically revised the article. Y.L. contributed to data acquisition and 395 critically revised the article. P.M. contributed to data acquisition and critically revised the article. 396 P.R.N. contributed to data acquisition and critically revised the article. O.A.A. contributed to 397 data acquisition and critically revised the article. E.C. contributed to data acquisition and 398 critically revised the article. A.Havdahl contributed to data acquisition and critically revised the 399 article. E. Molden critically revised the article. S.E.H. contributed to data acquisition, obtained 400 funding, and critically revised the article. K.F. provided support in data analysis and critically 401 revised the article. M.C.M. and A.Hernaez coordinated the project, contributed to data 402 interpretation, and critically revised the article. M.H.H. and A.Hernaez are the guarantors of 403 this study, accept full responsibility for the work and the conduct of the study, had access to 404 the data, and controlled the decision to publish.

#### 406 **REFERENCES**

407 1. Benevent J, Montastruc F, Damase-Michel C. The importance of
408 pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017;16:
409 1181–1190. doi:10.1080/14740338.2017.1363177

410 2. Molenaar NM, Bais B, Lambregtse-van den Berg MP, Mulder CL, Howell EA, Fox NS,
411 et al. The international prevalence of antidepressant use before, during, and after pregnancy:
412 A systematic review and meta-analysis of timing, type of prescriptions and geographical

413 variability. J Affect Disord. 2020;264: 82–89. doi:10.1016/j.jad.2019.12.014

Cohen JM, Cesta CE, Furu K, Einarsdóttir K, Gissler M, Havard A, et al. Prevalence
trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the
five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf. 2020;29:
913–922. doi:10.1002/pds.5035

Margulis AV, Hernandez-Diaz S, McElrath T, Rothman KJ, Plana E, Almqvist C, et al.
 Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth.
 PLoS One. 2019;14: e0214180. doi:10.1371/journal.pone.0214180

Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects
with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261: 579–588.
doi:10.1007/s00415-013-7239-x

Wartko PD, Weiss NS, Enquobahrie DA, Chan KCG, Stephenson-Famy A, Mueller BA,
 et al. Association of antidepressant continuation in pregnancy and infant birth weight. J Clin
 Psychopharmacol. 2021;Publish Ahead of Print: 403. doi:10.1097/jcp.00000000001410

Ashorn P, Ashorn U, Muthiani Y, Aboubaker S, Askari S, Bahl R, et al. Small vulnerable
newborns—big potential for impact. Lancet. 2023;401: 1692–1706. doi:10.1016/s01406736(23)00354-9

8. Evseenko D, Paxton JW, Keelan JA. Active transport across the human placenta:
impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol. 2006;2: 51–69.
doi:10.1517/17425255.2.1.51

Wang J-S, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, DeVane CL. The
emerging importance of transporter proteins in the psychopharmacological treatment of the
pregnant patient. Drug Metab Rev. 2007;39: 723–746. doi:10.1080/03602530701690390

436 10. Joshi AA, Vaidya SS, St-Pierre MV, Mikheev AM, Desino KE, Nyandege AN, et al.

437 Placental ABC transporters: Biological impact and pharmaceutical significance. Pharm Res.

438 2016;33: 2847–2878. doi:10.1007/s11095-016-2028-8

439 11. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human
440 placenta. Clin Pharmacokinet. 2004;43: 487–514. doi:10.2165/00003088-200443080-00001

Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic
polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical
implications: Update of the literature. Clin Pharmacokinet. 2015;54: 709–735.
doi:10.1007/s40262-015-0267-1

445 13. Goetzl L, Darbinian N, Merabova N, Devane LC, Ramamoorthy S. Gestational age
446 variation in human placental drug transporters. Front Pharmacol. 2022;13.
447 doi:10.3389/fphar.2022.837694

14. Daud ANA, Bergman JEH, Bakker MK, Wang H, de Walle HEK, Plösch T, et al.
Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental
transporter proteins. Pharmacogenomics. 2014;15: 1029–1041. doi:10.2217/pgs.14.62

451 15. Ewing G, Tatarchuk Y, Appleby D, Schwartz N, Kim D. Placental transfer of
452 antidepressant medications: Implications for postnatal adaptation syndrome. Clin
453 Pharmacokinet. 2015;54: 359–370. doi:10.1007/s40262-014-0233-3

454 16. Paltiel L, Haugan A, Skjerden T, et al. The biobank of the Norwegian Mother and Child
455 Cohort Study–present status. Norsk Epidemiologi. 2014;24: 29–35. Available:
456 https://www.ntnu.no/ojs/index.php/norepid/article/view/1755/1752

457

458 17. Corfield EC, Frei O, Shadrin AA, Rahman Z, Lin A, Athanasiu L, et al. The Norwegian
459 Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen
460 pipeline v.1. bioRxiv. 2022. p. 2022.06.23.496289. doi:10.1101/2022.06.23.496289

461 18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
462 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
463 guidelines for reporting observational studies. J Clin Epidemiol. 2008;61: 344–349.
464 doi:10.1016/j.jclinepi.2007.11.008

465 19. Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, et al. Cohort profile
466 update: The Norwegian mother and child cohort study (MoBa). Int J Epidemiol. 2016;45: 382–
467 388. doi:10.1093/ije/dyw029

468 20. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and
469 surveillance throughout 30 years: Thirty years' birth registration. Acta Obstet Gynecol Scand.
470 2000;79: 435–439. doi:10.1034/j.1600-0412.2000.079006435.x

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ.
2021;372: n71. doi:10.1136/bmj.n71

474 22. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population475 specific haplotype structure and linking correlated alleles of possible functional variants.
476 Bioinformatics. 2015;31: 3555–3557. doi:10.1093/bioinformatics/btv402

477 23. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or
478 pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug
479 exposure. J Clin Invest. 11 1999;104: 1441–1447. doi:10.1172/jci7963

Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms and
haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2
polymorphisms and epilepsy drug resistance. CNS Neurosci Ther. 2012;18: 647–651.
doi:10.1111/j.1755-5949.2012.00336.x

484 25. Sookoian S, Castaño G, Burgueño A, Gianotti TF, Pirola CJ. Association of the
485 multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis
486 of pregnancy. J Hepatol. 2008;48: 125–132. doi:10.1016/j.jhep.2007.08.015

487 26. Al-Enazy S, Ali S, Albekairi N, El-Tawil M, Rytting E. Placental control of drug delivery.

488 Adv Drug Deliv Rev. 2017;116: 63–72. doi:10.1016/j.addr.2016.08.002

489 27. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, 490 Fusch C, et al. Variable expression of mrp2 (abcc2) in human placenta: Influence of gestational 491 and cellular differentiation. Drug Dispos. 2005;33: age Metab 896-904. 492 doi:10.1124/dmd.104.003335

Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the
multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases
with advancing gestation. Placenta. 2006;27: 602–609. doi:10.1016/j.placenta.2005.05.007
Cohen JM, Selmer R, Furu K, Karlstad Ø. Interrupted time series analysis to assess
changes in prescription filling around conception and implications for exposure
misclassification. Pharmacoepidemiol Drug Saf. 2020;29: 745–749. doi:10.1002/pds.4974

- 499 30. Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and
- 500 SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target.
- 501 2012;20: 736–763. doi:10.3109/1061186x.2012.716847

# 503 SUPPORTING INFORMATION

### 504 TABLE OF CONTENTS

505	SUPPLEMENTAL MATERIALS
506	Search strategy of genetic variants
507	SUPPLEMENTAL TABLES
508	Supplemental Table 1. Expected risk allele for birth weight in efflux transporters
509	Supplemental Table 2. The articles detail the development of the expected risk allele for
510	the transporter score
511	Supplemental Table 3. STROBE checklist for cohort studies
512	SUPPLEMENTAL RESULTS
513	Supplemental Figure 1. Flow chart of the systematic literature review of genetic variants
514	on placental efflux transporters
515	Supplemental Figure 2. Differences in birth weight associated with pregnancy use of
516	antiseizure drugs due to ABCC2 individual genetic variants in the offspring
517	Supplemental Figure 3. Differences in birth weight associated with pregnancy use of
518	antiseizure drugs due to ABCB1 individual genetic variants in the mother
519	Supplemental Figure 4. Differences in birth weight associated with pregnancy use of
520	antidepressant medication and placental transporter genetic scores in the offspring39
521	Supplemental Figure 5. Differences in birth weight associated with pregnancy use of
522	antidepressant medication and placental transporter genetic scores in the mother40
523	SUPPLEMENTAL REFERENCES

### 525 SUPPLEMENTAL MATERIALS

#### 526

#### 527 Search strategy of genetic variants

528 All studies that examined the association between the placental transporters of interest and epilepsy or depression were researched. We systematically searched PubMed, Web of 529 530 Science, pharmacogenetic websites (https://www.pharmgkb.org) and GWAS catalog (https://www.ebi.ac.uk/gwas/home). All databases were searched using the Boolean method 531 532 with the following terms (1 AND 2 AND 3): 1) "antiseizure" OR "antiepilepsy" OR 533 "anticonvulsants" OR "antidepressant" OR "benzodiazepines"; 2) "polymorphism" OR "genetic 534 polymorphism" OR "genetic variant" OR "pharmacogenetics"; 3) "ATP binding cassette" or "ABCB1" OR "ABCC1" OR "ABCC2" OR "ABCG2" OR "ABCC5" OR "ABCC3". In addition, the 535 536 reference and discussions of all pooled articles were carefully scanned for additional 537 publications. We excluded studies: 1) not performed in humans; 2) not published in English; 3) 538 not published in scientific journals; and 4) focused on other drug groups.

#### SUPPLEMENTAL TABLES

#### Supplemental Table 1. Expected risk allele for birth weight in efflux transporters.

0	Determine	0	Desition	Expected risk allele for birth	Expected risk allele frequency in	<b>P</b> -famous	Conserved after linkage disequilibrium block
Gene	Polymorphism	Chromosome	Position	weight	Europeans	References	anaiysis
ABCB1	rs1045642	7	87138645	G	0.42	(1-9)	Yes
ABCB1	rs28401781	7	87148328	Т	0.12	(10)	No
ABCB1	rs2235067	7	87149922	Т	0.13	(11)	No
ABCB1	rs4148740	7	87152103	G	0.13	(12)	No
ABCB1	rs10280101	7	87153585	С	0.13	(11)	No
ABCB1	rs7787082	7	87157051	A	0.18	(11,13)	No
ABCB1	rs2032583	7	87160561	G	0.13	(11, 14-17)	No
					A: 0.41		
ABCB1	rs2032582	7	87160618	T/A	T: 0.02	(11, 15, 18-25)	No
ABCB1	rs4148739	7	87161049	С	0.13	(10-12)	No
ABCB1	rs11983225	7	87161520	С	0.13	(11)	No
ABCB1	rs10248420	7	87164986	G	0.18	(11, 26)	Yes
ABCB1	rs2235040	7	87165750	Т	0.13	(11,15,16)	No
ABCB1	rs12720067	7	87169356	Т	0.13	(11)	No
ABCB1	rs2032588	7	87179443	G	0.94	(27)	No, SNP not in MoBa
ABCB1	rs1128503	7	87179601	G	0.58	(5,12,22)	Yes
ABCB1	rs2235015	7	87199564	A	0.21	(11,17)	Yes
ABCB1	rs9282564	7	87229440	G	0.10	(28)	Yes
ABCB1	rs10245483	7	89637608	G	0.51	(29)	Yes
ABCC1	rs875740	16	16123048	С	0.35	(30)	Yes
ABCC1	rs212090	16	16236004	A	0.46	(31,32)	Yes
ABCC2	rs717620	10	101542578	С	0.79	(33-36)	Yes
ABCC2	rs4148386	10	101548468	G	0.44	(12)	No
ABCC2	rs2273697	10	101563815	G	0.80	(12, 37)	Yes
ABCC2	rs3740066	10	101604207	С	0.63	(12,33,38)	Yes
ABCG2	rs2231142	4	89052323	Т	0.10	(39,40)	Yes
ABCG2	rs3114020	4	89083666	С	0.40	(40)	Yes

# **Supplemental Table 2.** The articles detail the development of the expected risk allele for the transporter score.

Gene	Polymorphism	Drug	Study participants		Effect	P-value	Expected risk allele in the publication	Risk allele for birth weight	Reference
ABCB1		All antiseizure drugs	114 drug-resistant epilepsy patients, 213 seizure-free patients and 287 controls (Taiwan)	Efficacy	The C allele and the CC genotype were associated with drug resistance relative to the T allele and the TT genotype.	0.001	т		1
ABCB1		All antiseizure drugs	746 patients with epilepsy and 179 controls (China)	Efficacy	The TT genotype was associated with drug resistance	0.0009	G		2
ABCB1		All antiseizure drugs	220 patients with epilepsy and 220 controls (India)	Efficacy	The TT genotype was associated with drug resistance relative to the CC genotype.	0.001	G		3
ABCB1		Carbamazepine	3,293 patients with epilepsy. Meta analysis	Pharmacokinetics/ Efficacy	The T allele was associated with lower concentrations, lower absorption, and resistance to the drug activity.	0.004	т		4
ABCB1		Carbamazepine	2,126 patients with epilepsy. Meta-analysis	Efficacy	The T allele was associated to decreased plasma concentrations of the drug.	<0.05	G		5
ABCB1	rs1045642	Agomelatine	28 healthy volunteers (Spain)	Pharmacokinetics	The TT genotype was associated with lower concentrations or lower absorption of the drug.	0.047	G	G	6
ABCB1		All antiseizure drugs	8,716 patients with epilepsy, 4,037 drug- resistant epilepsy patients and 4,679 drug- responsive patients. Meta analysis	Efficacy	The T allele was associated with higher risk of drug resistance in the overall population and in Caucasians.	0.006	G		7
ABCB1		Carbamazepine	In vitro	Impact of T allele on the sensitivity, intracellular accumulation, and transepithelial permeability of antiseizure drugs	The recombinant T allele_cells showed higher resistance to carbamazepine compared with C allele_cells in the cytotoxicity assay. The intracellular accumulation of carbamazepine was significantly decreased in cells transfecting with recombinant T allele when compared with recombinant C allele_cells.	0.01	G		8
ABCB1		Carbamazepine	210 patients with epilepsy (China)	Pharmacokinetics	The GG genotype was associated with increased concentrations of carbamazepine relative to the AG genotype.	0.001	G		9
ABCB1	rs10248420	All antidepressants	256 patients with epilepsy (Europe)	Efficacy	The G allele was associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine relative to the A allele.	0.0095	G	G	11
ABCB1		Olanzapine	80 healthy volunteers (Spain)	Efficacy	The A allele was associated with decreased drug response compared to the G allele	0.047	G		26
ABCB1		All antiseizure drugs	90 patients with epilepsy (USA)	Pharmacokinetics	AA and AG genotypes were associated with increased clearance of carbamazepine relative to the GG genotype.	0.036	G		12
ABCB1	rs1128503	Lamotrigine	222 patients with epilepsy (Croatia)	Pharmacokinetics	The genotype CC was associated with higher lamotrigine concentrations compared to CT and TT genotypes.	0.021	G	G	22
ABCB1	1	Carbamazepine	2,126 patients with epilepsy. Meta-analysis	Efficacy	The CC genotype was associated with lower resistance to carbamazepine.	0.03	G	1	5
ABCB1	rs2235015	All antidepressants	339 patients with depression (European)	Efficacy	The A allele was associated with higher remission for P- glycoprotein antidepressants, citalopram, paroxetine, amitriptyline, and venlafaxine, relative to the C allele.	0.025	A	А	11

Gene	Polymorphism	Drug	Study participants		Effect	P-value	Expected risk allele in the publication	Risk allele for birth weight	Reference		
ABCB1		All antidepressants	73 patients with depressive disorder (Germany)	Efficacy	The A allele was associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine, relative to the C allele.	0.030	A		17		
ABCB1	rs9282564	Paroxetine	71 psychiatric patients (Switzerland)	Efficacy	The G allele was associated with greater clinical response.	0.043	G	G	28		
ABCB1	rs10245483	All antidepressants	683 patients with major depressive disorder (multisite)	Efficacy       The T allele was associated with less remission.         Efficacy       The C allele was associated with better treatment response.         Adverse effects       The A allele was associated with higher diastolic blood pressure (adverse effect)		0.001	G	G	29		
ABCC1	rs875740	All antiseizure drugs	199 patients from the Mayo Clinic Bipolar Disorder Biobank GWAS (USA)	Efficacy	The C allele was associated with better treatment response.	0.0089	С	С	30		
ABCC1	Clozapine 1:	137 medicated patients (Australia)	Adverse effects	The A allele was associated with higher diastolic blood pressure (adverse effect)	0.01	А		31			
ABCC1	rs212090	All antidepressants	148 patients with major depressive disorder (Australia)	Efficacy	The A allele was included int the pharmacogenetic guide group and associated with greater remission	0.0001	А	A	32		
ABCC2		All antiseizure drugs	537 patients with epilepsy (217 drug resistant patients and 320 drug responders) (China)	Efficacy	The TT genotype was associated with drug resistance	with drug resistance 0.001 C		33			
ABCC2	rs717620	All antiseizure drugs	4,300 patients with epilepsy (2,261 drug- resistant patients and 2,039 drug-responsive patients). Meta-analysis	Efficacy	The T allele was associated with drug resistance	0.0006	С	С	34		
ABCC2				All antiseizure drugs	254 patients with epilepsy (104 drug-resistant and 150 drug-responsive) (China)	Efficacy	The TT genotype was associated with drug resistance, relative to the CC genotype	0.001	С		35
ABCC2		All antiseizure drugs	1,842 patients with epilepsy. Meta-analysis	Efficacy	The T allele was associated with drug resistance.	0.002	С		36		
ABCC2		All antiseizure drugs	90 patients with epilepsy (USA)	Pharmacokinetics	AA and AG genotypes were associated with higher drug clearance relative to the GG genotype.	<0.05	G	6	12		
ABCC2	182273697	All antiseizure drugs	453 patients with epilepsy (China)	Efficacy	The A allele A was associated with drug resistance.	0.001	G	G	37		
ABCC2		All antiseizure drugs	90 patients with epilepsy (USA)	Pharmacokinetics	The G allele was associated with lower carbamazepine-10, 11- epoxide (metabolite): carbamazepine ratio.	0.008	С		12		
ABCC2	rs3740066	All antiseizure drugs	537 patients with epilepsy (217 drug resistant patients and 320 drug responders) (China)	Efficacy	CT and TT genotypes were associated with drug resistance relative to CC genotype.	0.038	С	с	33		
ABCC2		No drug	In vitro study	In vitro function of the transporter	The T allele was associated with a decreased function of the transporter.	0.017	С		38		

Gene	Polymorphism	Drug	Study participants		Effect	P-value	Expected risk allele in the publication	Risk allele for birth weight	Reference
ABCG2	rs2231142	Lamotrigine	112 patients with epilepsy (China)	Pharmacokinetics	The TT genotype was associated with increased concentrations of lamotrigine relative to GG and GT genotypes.	0.015	т	т	39
ABCG2		Lamotrigine	140 patients with epilepsy (China)	Pharmacokinetics	CA and AA genotypes were associated with higher concentrations of lamotrigine relative to the CC genotype.	<0.05	т		40
ABCG2	rs3114020	Lamotrigine	140 patients with epilepsy (China)	Pharmacokinetics	CC and CT genotypes were associated with increased concentrations of lamotrigine relative to the TT genotype.	0.01	С	С	40

548	Supplemental Table 3. STROBE checklist for cohort studies
549	

	Item No	Recommendation	Page No
Title and abstract			•
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction	I.		
Background/	2	Explain the scientific background and rationale for the investigation being reported	6-7
rationale	2	Ctate analific shipeting, including any me analified humathasas	07
Objectives Methods	3	State specific objectives, including any pre-specified hypotheses	6-7
Study design	1	Present key elements of study design early in the paper	6
Setting	5	Describe the setting locations and relevant dates including periods of recruitment exposure	0
County	Ű	follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-11
Data sources/	8	For each variable of interest, give sources of data and details of methods of assessment	8-11
measurement	0	(measurement). Describe comparability of assessment methods if there is more than one group	0.11
Dias Study cizo	9	Explain how the study size was arrived at	9-11 Fig 1
Quantitative variables	10	Explain how quantitative variables were handled in the analyses. If applicable, describe which	Fig. i
Quantitative variables		groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	-
		(d) If applicable, explain how loss to follow-up was addressed	-
Beaulta		(e) Describe any sensitivity analyses	11
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible	
1 antopanto	10	examined for eligibility, confirmed eligible, included in the study, completing follow-up, and	
		analyzed	Fig. 1
		(b) Give reasons for non-participation at each stage	Ű
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information	11, Table
		on exposures and potential confounders	1
		(b) Indicate number of participants with missing data for each variable of interest	-
Outcomo data	15	(c) Summarize follow-up time (e.g., average and total amount)	-
	15	Report numbers of outcome events of summary measures over time	14-18
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their	14-18
		precision (e.g., 55% confidence interval). Make clear which confounders were adjusted for and	Figures
		(b) Report category boundaries when continuous variables were categorized	14-18
			Figures
			2,3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity	18,
		analyses	Suppleme
			ntal
Discussion			figures 2-5
Kov rosulte	10	Summarize key results with reference to study objectives	10
Limitations	10	Discuss limitations of the study taking into account sources of potential bias or imprecision	19
	13	Discuss both direction and magnitude of any potential bias	20
interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	19-20
Generalizability	21	Discuss the generalizability (external validity) of the study results	20
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for	0.0
Ĭ		the original study on which the present article is based	23

### 551 SUPPLEMENTAL RESULTS

552

### 553 Supplemental Figure 1. Flow chart of the systematic literature review of genetic variants on

- 554 placental efflux transporters.
- 555



# 556 **Supplemental Figure 2.** Differences in birth weight associated with pregnancy use of

557 antiseizure drugs due to *ABCC2* individual genetic variants in the offspring.



#### 559 Supplemental Figure 3. Differences in birth weight associated with pregnancy use of

#### 560 antiseizure drugs due to ABCB1 individual genetic variants in the mother.





Difference in birth weight in users vs.non-users of antiseizure drugs in pregnancy Difference in birth weight in users vs.non-users of antiseizure drugs in pregnancy (95% confidence interval)

(95% confidence interval)

**Supplemental Figure 4.** Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in 563 the offspring.



**Supplemental Figure 5.** Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in 566 the mother.



(95% confidence interval)



# 567 SUPPLEMENTAL REFERENCES 568

Hung C-C, Jen Tai J, Kao P-J, Lin M-S, Liou H-H. Association of polymorphisms
 inNR1I2andABCB1genes with epilepsy treatment responses. Pharmacogenomics.
 2007;8: 1151–1158. doi:10.2217/14622416.8.9.1151

Kwan P, Baum L, Wong V, Ng PW, Lui CHT, Sin NC, et al. Association between
 ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy
 Behav. 2007;11: 112–117. doi:10.1016/j.yebeh.2007.04.013

Shaheen U, Prasad DKV, Sharma V, Suryaprabha T, Ahuja YR, Jyothy A, et al.
 Significance of MDR1 gene polymorphism C3435T in predicting drug response in
 epilepsy. Epilepsy Res. 2014;108: 251–256. doi:10.1016/j.eplepsyres.2013.11.009

578 4. Zhang M-L, Chen X-L, Bai Z-F, Zhao X, Li W-X, Wang X-Y, et al. ABCB1 c.3435C
579 > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine
580 concentration, metabolism, and pharmacoresistance in epileptic patients. Gene.
581 2021;805: 145907. doi:10.1016/j.gene.2021.145907

582 5. Fan Y-X, Zhang Z, Meng J-R, Yin S-J, Wang P, Zhou T, et al. Association of 583 ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A 584 meta-analysis. Epilepsy Res. 2021;177: 106785. doi:10.1016/j.eplepsyres.2021.106785

585 6. Saiz-Rodríguez M, Ochoa D, Belmonte C, Román M, Vieira de Lara D, Zubiaur 586 P, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine 587 pharmacokinetics. J Psychopharmacol. 2019;33: 522–531. 588 doi:10.1177/0269881119827959

589 7. Li M, Tan J, Yang X, Su L, Xie J, Liang B, et al. The ABCB1-C3435T
590 polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. Epilepsy
591 Res. 2014;108: 1052–1067. doi:10.1016/j.eplepsyres.2014.03.019

592 8. Shen X-M, Cheng J. Effects ofMDR1(C3435T) polymorphism on resistance,
593 uptake, and efflux to antiepileptic drugs. DNA Cell Biol. 2019;38: 250–255.
594 doi:10.1089/dna.2018.4553

595 9. Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and
596 metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese
597 patients with epilepsy. Pharmacogenomics. 2014;15: 1867–1879.
598 doi:10.2217/pgs.14.142

Huang X, Yu T, Li X, Cao Y, Li X, Liu B, et al. ABCB6, ABCB1 and ABCG1 genetic
polymorphisms and antidepressant response of SSRIs in Chinese depressive patients.
Pharmacogenomics. 2013;14: 1723–1730. doi:10.2217/pgs.13.151

602 11. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms
603 in the drug transporter gene ABCB1 predict antidepressant treatment response in
604 depression. Neuron. 2008;57: 203–209. doi:10.1016/j.neuron.2007.11.017

Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, et al.
Association of carbamazepine major metabolism and transport pathway gene
polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics.
2013;14: 35–45. doi:10.2217/pgs.12.180

Lee S-T, Ryu S, Kim S-R, Kim M-J, Kim S, Kim J-W, et al. Association study of
annotated genes for clozapine pharmacogenetics: Validation of preexisting studies
and identification of a new candidate gene, ABCB1, for treatment response. J Clin
Psychopharmacol. 2012;32: 441–448. doi:10.1097/jcp.0b013e31825ac35c

613 14. Breitenstein B, Brückl TM, Ising M, Müller-Myhsok B, Holsboer F, Czamara D.
614 ABCB1gene variants and antidepressant treatment outcome: A meta-analysis. Am J
615 Med Genet B Neuropsychiatr Genet. 2015;168: 274–283. doi:10.1002/ajmg.b.32309

de Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, et al. ABCB1
gene variants influence tolerance to selective serotonin reuptake inhibitors in a large
sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013;13:
349–353. doi:10.1038/tpj.2012.16

620 16. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM.

621 ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression.

622 Pharmacogenet Genomics. 2010;20: 467–475. doi:10.1097/fpc.0b013e32833b593a

Breitenstein B, Scheuer S, Brückl TM, Meyer J, Ising M, Uhr M, et al. Association
of ABCB1 gene variants, plasma antidepressant concentration, and treatment response:
Results from a randomized clinical study. J Psychiatr Res. 2016;73: 86–95.
doi:10.1016/j.jpsychires.2015.11.010

627 18. Gassó P, Rodríguez N, Mas S, Pagerols M, Blázquez A, Plana MT, et al. Effect
628 of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and
629 clinical improvement in children and adolescent patients. Pharmacogenomics J.
630 2014;14: 457–462. doi:10.1038/tpj.2014.12

Glauser TA, Holland K, O'Brien VP, Keddache M, Martin LJ, Clark PO, et al.
Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy: CAE
Pharmacogenetics. Ann Neurol. 2017;81: 444–453. doi:10.1002/ana.24886

Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, et al. ABCB1
(MDR1) gene polymorphisms are associated with the clinical response to paroxetine in
patients with major depressive disorder. Progress in Neuro-Psychopharmacology and
Biological Psychiatry. 2008;32: 398–404. doi:10.1016/j.pnpbp.2007.09.003

Mittal B, Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK. Pharmacogenomic
association study on the role of drug metabolizing, drug transporters and drug target
gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum
Genet. 2011;17: 32. doi:10.4103/0971-6866.80357

642 22. Lovrić M, Božina N, Hajnšek S, Kuzman MR, Sporiš D, Lalić Z, et al. Association
643 between lamotrigine concentrations and ABCB1 polymorphisms in patients with
644 epilepsy. Ther Drug Monit. 2012;34: 518–525. doi:10.1097/ftd.0b013e31826517c6

Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, et al. The
predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for
risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug
reactions. Pharmacogenomics J. 2018;18: 422–430. doi:10.1038/tpj.2017.38

Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, Allencherry PM, et al.
Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by
ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics.
2012;13: 1119–1127. doi:10.2217/pgs.12.86

Subenthiran S, Abdullah NR, Muniandy PK, Joseph JP, Cheong KC, Ismail Z, et
al. G2677T polymorphism can predict treatment outcome of Malaysians with complex
partial seizures being treated with Carbamazepine. Genet Mol Res. 2013;12: 5937–
5944. doi:10.4238/2013.november.26.3

26. Zubiaur P, Soria-Chacartegui P, Koller D, Navares-Gómez M, Ochoa D,
Almenara S, et al. Impact of polymorphisms in transporter and metabolizing enzyme
genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed
Pharmacother. 2021;133: 111087. doi:10.1016/j.biopha.2020.111087

Bet PM, Verbeek EC, Milaneschi Y, Straver DBM, Uithuisje T, Bevova MR, et al.
A common polymorphism in the ABCB1 gene is associated with side effects of PGPdependent antidepressants in a large naturalistic Dutch cohort. Pharmacogenomics J.
2016;16: 202–208. doi:10.1038/tpj.2015.38

665 28. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry J-M, Bondolfi G, et al. 666 CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and

 667
 therapeutic
 response.
 Ther
 Drug
 Monit.
 2008;30:
 474–482.

 668
 doi:10.1097/ftd.0b013e31817d6f5d

669 29. Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM.

670 ABCB1 genetic effects on antidepressant outcomes: A report from the iSPOT-D trial. Am

671 J Psychiatry. 2015;172: 751–759. doi:10.1176/appi.ajp.2015.14050680

30. Ho AM-C, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, et al. Moodstabilizing antiepileptic treatment response in bipolar disorder: A genome-wide
association study. Clin Pharmacol Ther. 2020;108: 1233–1242. doi:10.1002/cpt.1982

675 31. Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, et al. ABCB1 and
676 ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.
677 Pharmgenomics Pers Med. 2017;10: 235–242. doi:10.2147/pgpm.s142314

678 32. Singh AB. Improved antidepressant remission in major depression via a
679 pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol
680 Neurosci. 2015;13: 150–156. doi:10.9758/cpn.2015.13.2.150

33. Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms
and haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2
polymorphisms and epilepsy drug resistance. CNS Neurosci Ther. 2012;18: 647–651.
doi:10.1111/j.1755-5949.2012.00336.x

Gassing Stephenson, S

35. Xue T, Lu ZN. Association between the polymorphisms in the ATP-binding
cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese
Han population. Genet Mol Res. 2016;15. doi:10.4238/gmr15048752

691 36. Grover S, Kukreti R. A systematic review and meta-analysis of the role
692 of ABCC2variants on drug response in patients with epilepsy. Epilepsia. 2013;54: 936–
693 945. doi:10.1111/epi.12132

Ma C-L, Wu X-Y, Zheng J, Wu Z-Y, Hong Z, Zhong M-K. Association of SCN1A,
SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in
Chinese Han patients with epilepsy. Pharmacogenomics. 2014;15: 1323–1336.
doi:10.2217/pgs.14.89

38. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact
of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and
function. Pharmacogenomics J. 2011;11: 25–34. doi:10.1038/tpj.2010.20

39. Shen C-H, Zhang Y-X, Lu R-Y, Jin B, Wang S, Liu Z-R, et al. Specific OCT1 and
ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese
patients with epilepsy. Epilepsy Res. 2016;127: 186–190.
doi:10.1016/j.eplepsyres.2016.09.004

Zhou Y, Wang X, Li H, Zhang J, Chen Z, Xie W, et al. Polymorphisms of ABCG2,
ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy
patients. Drug Metab Pharmacokinet. 2015;30: 282–287.
doi:10.1016/j.dmpk.2015.05.002